The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

Novartis, a leading innovative medicines company, and the National Football League (NFL) announced an unprecedented partnership that names Novartis as the official first-in-category corporate ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

Novartis, a pharmaceuticals company, and the National Football League have announced an unprecedented partnership that names Novartis as the official first-in-category corporate pharmaceutical partner ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

The exclusive negotiating window for Visa, a 30-year NFL sponsor, to renew its deal with the league has expired, and the NFL ...

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...